510(k) K191973

Lumpipulse G CA19-9-N by Fujirebio Dianostics, Inc. — Product Code NIG

K191973 is an FDA 510(k) premarket notification submitted by Fujirebio Dianostics, Inc. for the device "Lumpipulse G CA19-9-N". The FDA issued a decision of Substantially Equivalent on Oct 22, 2019. The device falls under product code NIG (System, Test, Carbohydrate Antigen (Ca19-9), For Monitoring And Management Of Pancreatic Cancer), a Class II device regulated under 21 CFR 866.6010.

Clearance details

Decision
SESE (Substantially Equivalent)
Decision Date
Oct 22, 2019
Date Received
Jul 24, 2019
Clearance Type
Traditional
Expedited Review
No
Third Party Review
No

Device classification

Device Name
System, Test, Carbohydrate Antigen (Ca19-9), For Monitoring And Management Of Pancreatic Cancer
Device Class
Class II
Regulation Number
866.6010
Review Panel
IM
Submission Type
510(k)

An in vitro diagnostic test for the quantitative measurement of the CA 19-9 tumor associated antigen in human serum or plasma. The test is intended as an aid in the management of patients with confirmed pancreatic cancer and serial monitoring of their response to therapy and disease progression. The test should only be used in patients with serum and plasma CA 19-9 values above the cut-off at the time of diagnosis and in conjunction with other clinical methods.

Need the full FDA record for Fujirebio Dianostics, Inc.? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.

Get a free API key

How the connector works

Source: FDA 510(k) database entry for K191973. Report a data issue: hello@regdatalab.com.